Therapeutic Response

HER2-negative and PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Capecitabine in combination with Oxaliplatin in patients with Adenocarcinoma of the Gastroesophageal Junction.

View API

Statements

Source and description

View API